ADPT insider sells shares under a 10b5-1 plan. The filing lists three 10b5-1 dispositions by Susan Bobulsky: 11,000 shares on 06/04/2026, 5,000 shares on 06/11/2026, and 5,000 shares on 06/25/2026, with proceeds shown for each sale in the filing. The filing also lists 487 Restricted Stock Units (03/04/2022).
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benzeno, reported a series of option exercises and related stock sales. She exercised options for 114,329 shares of common stock at strike prices between $3.99 and $12.14 per share.
On June 26 and 29, 2026, she sold a total of 165,802 shares in open-market transactions at weighted-average prices of $21.00 and $21.14 per share. After these transactions, she directly holds 221,278 shares of Adaptive Biotechnologies common stock.
The filing notes that all transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Adaptive Biotechnologies Corp Chief Commercial Officer for MRD, Susan Bobulsky, reported an open-market sale of 5,000 shares of Common Stock at $20.50 per share. After this transaction, she directly holds 406,775 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating it was scheduled in advance.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an exercise-and-sale transaction in company stock. On June 25, 2026, she exercised stock options to acquire 52,084 shares of Common Stock at an exercise price of $7.80 per share, then sold 52,084 shares in an open-market transaction at a weighted-average price of $20.18 per share.
The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating they were scheduled in advance. Following the transactions, Griffin directly held 15,625 shares of Adaptive Biotechnologies Common Stock.
Sharon Benzeno submitted a Form 144 notice to sell Common Stock. The filing lists proposed sales tied to an exercise of stock options of 101,458 shares (dated 06/29/2026) and to Restricted Stock Units of 51,473 shares (dated 03/04/2026). The filing also reports a 10b5-1 sale of 11,034 shares on 06/26/2026 for $231,716.21. The cover lists 160,044,392 shares outstanding as of 06/29/2026 as a baseline figure.
ADPT submitted a Form 144 notice reporting proposed sales of common stock.
The filing lists a proposed sale of 5,000 common shares tied to previously exercised stock options dated 01/25/2022. The excerpt also discloses recent 10b5-1 sales by Susan Bobulsky: 11,000 shares on 06/04/2026 for $198,000 and 5,000 shares on 06/11/2026 for $95,000.
Adaptive Biotechnologies Corporation issued $345 million of 0% Convertible Senior Notes due 2031 in a private offering to qualified institutional buyers. The notes are senior unsecured obligations, carry no cash interest, and are convertible into common stock at an initial price of about $24.11 per share, a 40% premium to the June 16, 2026 share price of $17.22.
The company expects net proceeds of about $334.5 million, of which it used $156.9 million to repay in full its revenue interest obligations under the OrbiMed Purchase Agreement, $25.6 million to fund capped call transactions, and $25.0 million to repurchase 1,451,800 shares of common stock in privately negotiated transactions. The remainder will support general corporate purposes and initiatives in its minimal residual disease (MRD) business. Capped call transactions with a cap price of $34.44 per share are designed to reduce potential dilution or excess cash payments upon conversion, subject to limitations.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of company common stock. He sold 100,000 shares on June 15, 2026 at a weighted-average price of $17.37 per share and 6,160 shares on June 16, 2026 at a weighted-average price of $18.01 per share.
All transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After these sales, Robins directly holds 1,405,898 shares of Adaptive Biotechnologies common stock.